Enabling more targeted PTSD treatment
HMNC Brain Health’s PTSD blood test allows for the earlier identification of individuals at risk for developing post-traumatic stress disorder (PTSD) and supports the prevention of harmful coping behavior – including suicide. In addition, a much more personalized treatment can be achieved as the information provided to clinicians supports therapeutic decisions.
Post-traumatic stress disorder is a serious disease that may occur in people who have experienced or witnessed a traumatic event such as natural disasters, serious accidents, combat operations, or terrorist acts.
According to estimations, 3.5% of US adults are affected by PTSD every year.
The test, designed as DNA array and developed by researchers at the Icahn School of Medicine at Mount Sinai and the Max Planck Institute of Psychiatry, examines the expression of 3 biomarkers of PTSD for cortisol dysregulation.
In 2018, the PTSD test was out-licensed to the renowned US veteran-led biotech company Polaris Genomics to further drive the development.